SCHEMBL1726609

SCHEMBL1726609

Cc1cccc2sc(NC(=O)c3ccc(S(=O)(=O)C4CCc5ccccc5N4)cc3)nc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.54
ALDH1A1 P00352 6/20 0.54
SMN1; SMN2 Q16637 6/20 0.54
KDM4E B2RXH2 5/20 0.54
HPGD P15428 2/20 0.54
RECQL P46063 1/20 0.54
LMNA P02545 7/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
RAB9A P51151 3/20 0.50
MEN1 O00255 4/20 0.49
MAPK1 P28482 4/20 0.49
KMT2A Q03164 4/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
RXFP1 Q9HBX9 1/20 0.48
TP53 P04637 4/20 0.47
POLB P06746 2/20 0.46
HTT P42858 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1728185 0.87 MAPT (0.55) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1727655 0.84 SMN1; SMN2 (0.59) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1728196 0.82 LMNA (0.50) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1727944 0.81 LRRK2 (0.59) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1726674 0.79 NPC1 (0.52) MAPTSMN1; SMN2LMNARAB9AMEN1
SCHEMBL1728020 0.77 KMT2A (0.60) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1726841 0.77 PHGDH (0.60) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5713545 0.76 MAPT (0.67) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1727649 0.76 MEN1 (0.60) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1726833 0.75 KDM4A (0.60) MAPTALDH1A1SMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403499-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL Stemsynergy Therapeutics, Inc (US) 2012-01-11 EP disclosed
WO-2010101964-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2010-09-10 WO disclosed